1. Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review 
Nolan J. Maloney, BS, Lisa D. Hisaw, MD, Scott Worswick, MD 
Journal of the American Academy of Dermatology 
Volume 79, Issue 3, Pages (September 2018)
DOI: /j.jaad
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Selection methodology for systematic review on type I PRP treated with biologics. PubMed search used: “pityriasis rubra pilaris” AND “TNF” or “biologic” or “etanercept” or “adalimumab” or “infliximab” or “ustekinumab” or “secukinumab.” Inclusion criteria included articles in English and description of the biologic regimen, primary improvement, and total duration to improvement. PRP, Pityriasis rubra pilaris; TNF, tumor necrosis factor.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions